Hepamerz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

## Hepamerz (L-Ornithine L-Aspartate) ### Overview Hepamerz is a combination of two amino acids, L-ornithine and L-aspartate, used in the management of hepatic encephalopathy. ### Primary Indications * Treatment of latent and overt hepatic encephalopathy associated with hyperammonemia. ### Adult Dosing * **Oral:** Typically 3-6 grams (equivalent to one to two sachets or 10-20 mL of oral solution) three times daily. Doses can be adjusted based on patient response and ammonia levels. * **Intravenous (IV):** Usually 5 grams (1 ampoule) diluted in 500 mL of 5% dextrose or saline, administered over 30-60 minutes, twice daily. Higher doses of up to 10 grams per day have been used in severe cases. Specific IV dosing regimens may vary and should be guided by local protocol. ### Pediatric Dosing * Data on pediatric dosing is limited. Use should be based on clinical judgment and specialist consultation. Some sources suggest doses similar to adults on a weight-based calculation (e.g., 100-200 mg/kg/day divided into 3 doses), but this is not universally established. ### Dose Adjustments * No specific dose adjustments are routinely recommended for renal or hepatic impairment, as the drug is primarily metabolized and excreted by the liver and kidneys. However, caution and close monitoring are advised in patients with severe renal or hepatic dysfunction due to potential accumulation. ### Contraindications * Severe hypersensitivity to L-ornithine or L-aspartate. * Rarely, severe kidney failure (oliguria or anuria). ### Adverse Effects * Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea, flatulence. * Rare: Dizziness, headache, fatigue, muscle pain. ### Key Drug Interactions * No significant drug interactions have been widely reported. However, monitor patients receiving other hepatically metabolized drugs. ### Monitoring * Serum ammonia levels. * Liver function tests. * Renal function tests. * Neurological status. ### Clinical Pearls * The efficacy of Hepamerz is linked to its ability to reduce ammonia levels by promoting ammonia detoxification in the liver (urea cycle) and peripheral tissues (ornithine decarboxylase pathway). * Oral administration may be preferred for long-term management of latent hepatic encephalopathy. * IV administration is typically used for more acute or severe episodes of hepatic encephalopathy. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines before administering any medication.*